~ Buy the GIAPREZA (angiotensin ii acetate) Drug Profile, 2024 PDF Report in the Report Store ~

GIAPREZA Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Giapreza, and what generic alternatives are available?

Giapreza is a drug marketed by La Jolla Pharma and is included in one NDA. There are eleven patents protecting this drug and one Paragraph IV challenge.

This drug has forty-seven patent family members in twenty-three countries.

The generic ingredient in GIAPREZA is angiotensin ii acetate. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the angiotensin ii acetate profile page.

DrugPatentWatch^® Generic Entry Outlook for Giapreza

Giapreza was eligible for patent challenges on December 21, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 16, 2029. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

< Available with Subscription >

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for GIAPREZA?
What are the global sales for GIAPREZA?
What is Average Wholesale Price for GIAPREZA?

Summary for GIAPREZA

International Patents:	47
US Patents:	11
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	57
Clinical Trials:	8
Patent Applications:	7,510
Drug Prices:	Drug price information for GIAPREZA
What excipients (inactive ingredients) are in GIAPREZA?	GIAPREZA excipients list
DailyMed Link:	GIAPREZA at DailyMed

Drug patent expirations by year for GIAPREZA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for GIAPREZA

Generic Entry Date for GIAPREZA^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: ⤷ Sign Up NDA: 209360 Dosage: SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for GIAPREZA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Kingman Regional Medical Center	Phase 4
National Center for Advancing Translational Science (NCATS)	Phase 4
University of New Mexico	Phase 4

See all GIAPREZA clinical trials

Pharmacology for GIAPREZA

Drug Class	Vasoconstrictor
Physiological Effect	Vasoconstriction

Paragraph IV (Patent) Challenges for GIAPREZA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GIAPREZA	Injection	angiotensin ii acetate	2.5 mg/mL	209360	1	2021-12-21

US Patents and Regulatory Information for GIAPREZA

GIAPREZA is protected by sixteen US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of GIAPREZA is ⤷ Sign Up.

This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting GIAPREZA

Angiotensin II alone or in combination for the treatment of hypotension
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: MAINTAINING MEAN ARTERIAL PRESSURE OF ABOUT 65 MMHG OR ABOVE WITH ABOUT 1 NG/KG/MIN TO ABOUT 40 NG/KG/MIN ANGIOTENSIN II IN HYPOTENSIVE PATIENTS TREATED WITH VASOPRESSIN OR A VASOPRESSIN ANALOGUE AND REDUCING VASOPRESSIN OR VASOPRESSIN ANALOGUE USE

Method of treating low blood pressure
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING HYPOTENSION WITH ABOUT 20 NG/KG/MIN TO ABOUT 40 NG/KG/MIN ANGIOTENSIN II IN A HUMAN SUBJECT HAVING SEPTIC SHOCK

Angiotensin II alone or in combination for the treatment of hypotension
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II AT AN INITIAL RATE OF ABOUT 20 NG/KG/MIN AND TITRATING DOWN TO ACHIEVE AND/OR MAINTAIN A MAP OF ABOUT 65 MM HG OR ABOVE

Method of treating low blood pressure
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II WITH AN INITIAL RATE OF ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN IN A SUBJECT HAVING REFRACTORY HYPOTENSION OR SEVERE HYPOTENSION, AND TITRATING THE RATE UP

Method of treating low blood pressure
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: INCREASING BLOOD PRESSURE WITH A RATE OF ABOUT 20 NG/KG/MIN TO ABOUT 40 NG/KG/MIN ANGIOTENSIN II IN A HUMAN SUBJECT HAVING SEPTIC SHOCK

Method of treating low blood pressure
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: INCREASING BLOOD PRESSURE WITH AN INITIAL RATE OF ABOUT 20 NG/KG/MIN ANGIOTENSIN II IN A HUMAN SUBJECT HAVING SEPTIC SHOCK, AND TITRATING THE RATE UP.

Angiotensin II alone or in combination for the treatment of hypotension
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING SEPTIC SHOCK WITH ANGIOTENSIN II

Angiotensin II alone or in combination for the treatment of hypotension
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING DISTRIBUTIVE SHOCK WITH ANGIOTENSIN II

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING HYPOTENSION WITH ANGIOTENSIN II IN A PATIENT RECEIVING AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: INCREASING BLOOD PRESSURE IN A PATIENT HAVING DISTRIBUTIVE SHOCK

Angiotensin II alone or in combination for the treatment of hypotension
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING HIGH OUTPUT SHOCK WITH ANGIOTENSIN II BY INCREASING MEAN ARTERIAL PRESSURE IN PATIENTS TREATED WITH CATECHOLAMINES AND REDUCING CATECHOLAMINE USE

Angiotensin II alone or in combination for the treatment of hypotension
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: MAINTAINING MEAN ARTERIAL PRESSURE OF ABOUT 65 MMHG OR HIGHER WITH ANGIOTENSIN II IN SHOCK PATIENTS TREATED WITH CATECHOLAMINES AND REDUCING CATECHOLAMINE USE

Method of treating low blood pressure
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING REFRACTORY HYPOTENSION WITH ABOUT 20 NG/KG/MIN ANGIOTENSIN II IN A PATIENT RECEIVING VASOPRESSOR

Method of treating low blood pressure
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING REFRACTORY HYPOTENSION WITH ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN ANGIOTENSIN II IN A PATIENT RECEIVING VASOPRESSOR

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
La Jolla Pharma	GIAPREZA	angiotensin ii acetate	SOLUTION;INTRAVENOUS	209360-002	Dec 21, 2017		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
La Jolla Pharma	GIAPREZA	angiotensin ii acetate	SOLUTION;INTRAVENOUS	209360-001	Dec 21, 2017		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
La Jolla Pharma	GIAPREZA	angiotensin ii acetate	SOLUTION;INTRAVENOUS	209360-002	Dec 21, 2017		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for GIAPREZA

See the table below for patents covering GIAPREZA around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2017120438		⤷ Sign Up
Eurasian Patent Organization	202092463	АНГИОТЕНЗИН II САМОСТОЯТЕЛЬНО ИЛИ В КОМБИНАЦИИ ДЛЯ ЛЕЧЕНИЯ ГИПОТЕНЗИИ	⤷ Sign Up
Taiwan	201733610	Methods for administering angiotensin II	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration